Hautmann S, Beitz S, Naumann M, Lützen U, Seif C, Stübinger S H, van der Horst C, Braun P M, Leuschner I, Henze E, Jünemann K P
Klinik für Urologie und Kinderurologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Urologe A. 2008 Mar;47(3):299-303. doi: 10.1007/s00120-008-1652-2.
Extended lymph node dissection during radical prostatectomy for prostate cancer remains a disputed area. Sentinel lymph scans help identify the first lymph node stages in the lymph drainage of the prostate. This study was designed to investigate the detection rate of lymph node metastasis by extended lymph node dissection and sentinel lymph node scanning in patients undergoing radical retropubic prostatectomy (RRP) for localized prostate cancer. In this study at our department from 2005 to 2006, a total of 108 patients with localized prostate carcinoma were treated with radical prostatectomy including extended lymph node dissection. A sentinel lymph node scan with 160 MBq of technetium-99m-Nanocoll (Tc) was performed 1 day before surgery. A C-Trak gamma probe (AEA Technologies, Morgan Hills, CA, USA) was used intraoperatively to detect the sentinel lymph nodes. Scan findings were correlated with tumor stage, Gleason score, prostate-specific antigen (PSA) level, and histological lymph node status. Scans revealed sentinel lymph nodes on the film 2 h after Tc administration in 98 of 108 patients (91%). Histologically proven lymph node metastases were detected in 15 of those 98 patients (15%) with a positive sentinel scan. Those 15 patients had a PSA level greater than 10 ng/ml or a Gleason score greater than 6 and at least a pT2 tumor. Specifically, six patients had a pT2 tumor, and nine patients had a pT3 tumor. Of patients placed in a risk group defined as PSA above 10 ng/ml or Gleason score greater than 6, 15 out of 50 patients (30%) had sentinel positive lymph nodes with metastasis. These data suggest that extended sentinel lymph node dissection helps identify lymph node metastasis in patients with PSA above 10 ng/ml or a Gleason score above 6 in 30% of cases. Further studies will show whether these numbers will hold true in patients undergoing radical prostatectomy for prostate cancer.
前列腺癌根治性前列腺切除术中扩大淋巴结清扫术仍是一个存在争议的领域。前哨淋巴结扫描有助于识别前列腺淋巴引流中的首个淋巴结分期。本研究旨在调查接受耻骨后根治性前列腺切除术(RRP)治疗局限性前列腺癌的患者中,扩大淋巴结清扫术和前哨淋巴结扫描对淋巴结转移的检出率。在我们科室2005年至2006年的这项研究中,共有108例局限性前列腺癌患者接受了包括扩大淋巴结清扫术在内的根治性前列腺切除术。术前1天进行了160MBq的99m锝-纳米胶体(Tc)前哨淋巴结扫描。术中使用C-Trakγ探测器(美国加利福尼亚州摩根山的AEA技术公司)检测前哨淋巴结。扫描结果与肿瘤分期、Gleason评分、前列腺特异性抗原(PSA)水平及组织学淋巴结状态相关。注射Tc后2小时,108例患者中有98例(91%)在胶片上显示出前哨淋巴结。在这98例前哨扫描阳性的患者中,有15例(15%)经组织学证实有淋巴结转移。这15例患者的PSA水平大于10ng/ml或Gleason评分大于6,且至少为pT2期肿瘤。具体而言,6例为pT2期肿瘤,9例为pT3期肿瘤。在被定义为PSA高于10ng/ml或Gleason评分大于6的风险组患者中,50例患者中有15例(30%)前哨淋巴结阳性并伴有转移。这些数据表明,扩大前哨淋巴结清扫术有助于在30%的PSA高于10ng/ml或Gleason评分高于6的患者中识别淋巴结转移。进一步的研究将表明这些数据在接受前列腺癌根治性前列腺切除术的患者中是否仍然适用。